Using a viral treatment to lower eye pressure for glaucoma patients
Virally expressed Stanniocalcin-1 for long-term intraocular pressure reduction
This study is looking at a new way to help people with glaucoma by using a special virus to deliver a hormone that could lower eye pressure for a longer time, making it easier for those who have trouble with regular eye drops.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10909144 on NIH RePORTER |
What this research studies
This research investigates the use of a viral vector to deliver Stanniocalcin-1, a peptide hormone that has shown promise in reducing intraocular pressure (IOP), a key factor in glaucoma. By expressing this hormone in a sustained manner, the goal is to provide a long-term solution for patients who struggle with traditional glaucoma treatments, such as eye drops. The study aims to evaluate the effectiveness of this approach in lowering IOP and potentially preventing blindness associated with glaucomatous optic neuropathy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glaucoma who experience difficulty managing their intraocular pressure with current treatments.
Not a fit: Patients who do not have glaucoma or those whose IOP is already well-controlled with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, long-lasting treatment option for patients with glaucoma, reducing their reliance on daily eye drops.
How similar studies have performed: Previous research has shown that similar approaches using viral vectors for gene therapy have been successful in other conditions, indicating potential for success in this novel application.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Roddy, Gavin W — Mayo Clinic Rochester
- Study coordinator: Roddy, Gavin W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.